Bekir Tanriover1, Song Zhang2, Malcolm MacConmara3, Ang Gao2, Burhaneddin Sandikci4, Mehmet U S Ayvaci5, Mutlu Mete6, Demetra Tsapepas7, Nilum Rajora8, Prince Mohan9, Ronak Lakhia8, Christopher Y Lu8, Miguel Vazquez8. 1. Division of Nephrology, bekir.tanriover@utsouthwestern.edu. 2. Department of Clinical Sciences, and. 3. Center for Abdominal Organ Transplantation, University of Texas Southwestern Medical Center, Dallas, Texas; 4. Booth School of Business, University of Chicago, Illinois; 5. Information Systems, University of Texas, Dallas, Texas; 6. Computer Science and Information Systems, Texas A&M University, Commerce, Texas; 7. Division of Pharmacy, New York Presbyterian Hospital, New York, New York; and. 8. Division of Nephrology. 9. Division of Nephrology, Medical University of South Carolina, Charleston, South Carolina.
Abstract
BACKGROUND AND OBJECTIVES: Induction therapy with IL-2 receptor antagonist (IL2-RA) is recommended as a first line agent in living donor renal transplantation (LRT). However, use of IL2-RA remains controversial in LRT with tacrolimus (TAC)/mycophenolic acid (MPA) with or without steroids. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The Organ Procurement and Transplantation Network registry was studied for patients receiving LRT from 2000 to 2012 maintained on TAC/MPA at discharge (n=36,153) to compare effectiveness of IL2-RA to other induction options. The cohort was initially divided into two groups based on use of maintenance steroid at time of hospital discharge: steroid (n=25,996) versus no-steroid (n=10,157). Each group was further stratified into three categories according to commonly used antibody induction approach: IL2-RA, rabbit anti-thymocyte globulin (r-ATG), and no-induction in the steroid group versus IL2-RA, r-ATG and alemtuzumab in the no-steroid group. The main outcomes were the risk of acute rejection at 1 year and overall allograft failure (graft failure or death) post-transplantation through the end of follow-up. Propensity score-weighted regression analysis was used to minimize selection bias due to non-random assignment of induction therapies. RESULTS: Multivariable logistic and Cox analysis adjusted for propensity score showed that outcomes in the steroid group were similar between no-induction (odds ratio [OR], 0.96; 95% confidence interval [95% CI], 0.86 to 1.08 for acute rejection; and hazard ratio [HR], 0.99; 95% CI, 0.90 to 1.08 for overall allograft failure) and IL2-RA categories. In the no-steroid group, odds of acute rejection with r-ATG (OR, 0.73; 95% CI, 0.59 to 0.90) and alemtuzumab (OR, 0.53; 95% CI, 0.42 to 0.67) were lower; however, overall allograft failure risk was higher with alemtuzumab (HR, 1.27; 95% CI, 1.03 to 1.56) but not with r-ATG (HR, 1.19; 95% CI, 0.97 to 1.45), compared with IL2-RA induction. CONCLUSIONS: Compared with no-induction therapy, IL2-RA induction was not associated with better outcomes when TAC/MPA/steroids were used in LRT recipients. r-ATG appears to be an acceptable and possibly the preferred induction alternative for IL2-RA in steroid-avoidance protocols.
BACKGROUND AND OBJECTIVES: Induction therapy with IL-2 receptor antagonist (IL2-RA) is recommended as a first line agent in living donor renal transplantation (LRT). However, use of IL2-RA remains controversial in LRT with tacrolimus (TAC)/mycophenolic acid (MPA) with or without steroids. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The Organ Procurement and Transplantation Network registry was studied for patients receiving LRT from 2000 to 2012 maintained on TAC/MPA at discharge (n=36,153) to compare effectiveness of IL2-RA to other induction options. The cohort was initially divided into two groups based on use of maintenance steroid at time of hospital discharge: steroid (n=25,996) versus no-steroid (n=10,157). Each group was further stratified into three categories according to commonly used antibody induction approach: IL2-RA, rabbit anti-thymocyte globulin (r-ATG), and no-induction in the steroid group versus IL2-RA, r-ATG and alemtuzumab in the no-steroid group. The main outcomes were the risk of acute rejection at 1 year and overall allograft failure (graft failure or death) post-transplantation through the end of follow-up. Propensity score-weighted regression analysis was used to minimize selection bias due to non-random assignment of induction therapies. RESULTS: Multivariable logistic and Cox analysis adjusted for propensity score showed that outcomes in the steroid group were similar between no-induction (odds ratio [OR], 0.96; 95% confidence interval [95% CI], 0.86 to 1.08 for acute rejection; and hazard ratio [HR], 0.99; 95% CI, 0.90 to 1.08 for overall allograft failure) and IL2-RA categories. In the no-steroid group, odds of acute rejection with r-ATG (OR, 0.73; 95% CI, 0.59 to 0.90) and alemtuzumab (OR, 0.53; 95% CI, 0.42 to 0.67) were lower; however, overall allograft failure risk was higher with alemtuzumab (HR, 1.27; 95% CI, 1.03 to 1.56) but not with r-ATG (HR, 1.19; 95% CI, 0.97 to 1.45), compared with IL2-RA induction. CONCLUSIONS: Compared with no-induction therapy, IL2-RA induction was not associated with better outcomes when TAC/MPA/steroids were used in LRT recipients. r-ATG appears to be an acceptable and possibly the preferred induction alternative for IL2-RA in steroid-avoidance protocols.
Authors: Marieke Dingena Spreeuwenberg; Anna Bartak; Marcel A Croon; Jacques A Hagenaars; Jan J V Busschbach; Helene Andrea; Jos Twisk; Theo Stijnen Journal: Med Care Date: 2010-02 Impact factor: 2.983
Authors: N Ahsan; D Hricik; A Matas; S Rose; S Tomlanovich; A Wilkinson; M Ewell; M McIntosh; D Stablein; E Hodge Journal: Transplantation Date: 1999-12-27 Impact factor: 4.939
Authors: E Steve Woodle; V Ram Peddi; Stephen Tomlanovich; Shamkant Mulgaonkar; Paul C Kuo Journal: Clin Transplant Date: 2009-11-20 Impact factor: 2.863
Authors: Nasimul Ahsan; Michael J Holman; Mark V Jarowenko; Mohammad S Razzaque; Harold C Yang Journal: Am J Transplant Date: 2002-07 Impact factor: 8.086
Authors: A J Matas; J M Smith; M A Skeans; B Thompson; S K Gustafson; M A Schnitzler; D E Stewart; W S Cherikh; J L Wainright; J J Snyder; A K Israni; B L Kasiske Journal: Am J Transplant Date: 2014-01 Impact factor: 8.086
Authors: Rhys D R Evans; James H Lan; Matthew Kadatz; Sandeep Brar; Doris T Chang; Lachlan McMichael; Jagbir Gill; John S Gill Journal: Clin J Am Soc Nephrol Date: 2022-02 Impact factor: 10.614
Authors: Bekir Tanriover; Vishal Jaikaransingh; Malcolm P MacConmara; Justin R Parekh; Swee-Ling Levea; Venkatesh K Ariyamuthu; Song Zhang; Ang Gao; Mehmet U S Ayvaci; Burhaneddin Sandikci; Nilum Rajora; Vaqar Ahmed; Christopher Y Lu; Sumit Mohan; Miguel A Vazquez Journal: Clin J Am Soc Nephrol Date: 2016-06-30 Impact factor: 8.237
Authors: Zahra Gharibi; Mehmet U S Ayvaci; Michael Hahsler; Tracy Giacoma; Robert S Gaston; Bekir Tanriover Journal: Transplantation Date: 2017-06 Impact factor: 4.939
Authors: Vikas R Dharnidharka; Abhijit S Naik; David A Axelrod; Mark A Schnitzler; Zidong Zhang; Sunjae Bae; Dorry L Segev; Daniel C Brennan; Tarek Alhamad; Rosemary Ouseph; Ngan N Lam; Mustafa Nazzal; Henry Randall; Bertram L Kasiske; Mara McAdams-Demarco; Krista L Lentine Journal: Transpl Int Date: 2017-11-02 Impact factor: 3.782
Authors: Vishnu S Potluri; Chirag R Parikh; Isaac E Hall; Joseph Ficek; Mona D Doshi; Isabel Butrymowicz; Francis L Weng; Bernd Schröppel; Heather Thiessen-Philbrook; Peter P Reese Journal: Clin J Am Soc Nephrol Date: 2015-12-14 Impact factor: 8.237